Merck (NYSE:MRK) reported a series of positive late stage clinical trial results for oncology and HIV therapies, including new Phase 3 data for KEYTRUDA and WELIREG regimens in kidney, ovarian, and ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...

Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

Feb 23 () - Merck is splitting its human-health business into two ‌divisions to offset pressures ‌related to the loss of ...

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pharmaceutical ...

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

This underscores the US drugmaker’s push to diversify beyond its blockbuster drug Read more at The Business Times.